1-20 of 26
Stephen R. Wedge
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1108: A novel, selective inhibitor of DNA-dependent protein kinase (DNA-PK) potentiates the effects of DNA-damaging therapies in hepatocellular carcinoma

Catherine E. Willoughby, Huw D. Thomas, Tommy Rennison, Celine Cano, Helen L. Reeves, Stephen R. Wedge
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1108.
DOI: https://doi.org/10.1158/1538-7445.AM2017-1108
Published: 01 July 2017
View article
Journal Articles

Abstract 325: Evaluating the consequences of MCT1 inhibition in Burkitt lymphoma following treatment with AZD3965

Richard A. Noble, Natalie Bell, Helen Blair, Huw D. Thomas, Simon Bomken, Susan E. Critchlow, Stephen R. Wedge
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 325.
DOI: https://doi.org/10.1158/1538-7445.AM2016-325
Published: 15 July 2016
View article
Journal Articles

Abstract 5451: Profiling inhibitors of MDM2:p53 and MDMX:p53 in relation to MDMX protein levels

Sue Tudhope, Yan Zhao, Anita Wittner, Elaine Wilmore, Annalisa Bertoli, Santosh Adhikari, Suzannah J. Harnor, Fabio Del Bello, Alessandro Piergentili, John Lunec, Ian R. Hardcastle, Roger J. Griffin, Bernard R. Golding, Celine Cano, David R. Newell, Stephen R. Wedge
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 5451.
DOI: https://doi.org/10.1158/1538-7445.AM2014-5451
Published: 01 October 2014
View article
Journal Articles

Abstract 598: Use of fluorescent imaging to monitor drug responses in mouse models of tumorigenesis.

Lucy A. Balderstone, Morwenna Muir, Arkadiusz Welman, Alan Serrels, Stephen R. Wedge, Val Brunton
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 598.
DOI: https://doi.org/10.1158/1538-7445.AM2013-598
Published: 15 April 2013
View article
Journal Articles

Abstract 3848: Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer

Sarah A. Loddick, Rob Bradbury, Nicola Broadbent, Hayley Campbell, Luke Gaughan, Jim Growcott, Natalie Stratton, Elizabeth Mouchet, Daniel O'Neill, Al Rabow, David Robinson, Craig N. Robson, Sarah J. Ross, Fadhel Shaheen, Dawn Trueman, Graeme Walker, Stephen R. Wedge, Nigel A.N. Brooks
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3848.
DOI: https://doi.org/10.1158/1538-7445.AM2012-3848
Published: 15 April 2012
View article
Journal Articles

Abstract 1564: Investigating the interaction of tumor xenografts with their microenvironment by combining human- and mouse- specific assays with high throughput RT-qPCR

Matthew Farren, Susie Weston, Helen Brown, Steve Powell, Robert Shaw, Neil R. Smith, Susan Lovick, Susan Ashton, Stephen R. Wedge, Simon T. Barry
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 1564.
DOI: https://doi.org/10.1158/1538-7445.AM2011-1564
Published: 15 April 2011
View article
Journal Articles

Abstract 4123: Monocarboxylate transporter 4 expression is a prognostic factor for radiotherapy outcome in squamous cell carcinoma of the head and neck

Amy L. Chadwick, Chris Womack, Gillian Watkins, Becky M. Bola, Nick Slevin, Jarrod Homer, Paul Smith, Susan E. Critchlow, Catharine M. West, Stephen R. Wedge, Ian J. Stratford
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4123.
DOI: https://doi.org/10.1158/1538-7445.AM2011-4123
Published: 15 April 2011
View article
Journal Articles

Abstract 1372: Cediranib alone and in combination with mechanistically distinct antitumor therapies in vivo

Juliane M. Jürgensmeier, Jane Kendrew, Rajesh Odedra, Armelle Logie, Philippa Wood, Paula Valentine, Sharon Barnett, Robert W. Wilkinson, Donald J. Ogilvie, Paul Elvin, Paul Smith, Anderson Ryan, Stephen R. Wedge
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 1372.
DOI: https://doi.org/10.1158/1538-7445.AM10-1372
Published: 15 April 2010
View article
Journal Articles

Abstract 5635: Analysis of monocarboxylate transporter 4 as a biomarker shows prognostic significance as an indicator of radiotherapy in squamous cell carcinoma of the head and neck

Amy L. Chadwick, Christopher Womack, Catharine M. West, Susan E. Critchlow, Stephen R. Wedge, Ian J. Stratford
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 5635.
DOI: https://doi.org/10.1158/1538-7445.AM10-5635
Published: 15 April 2010
View article
Journal Articles

The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis

Caroline A. Heckman, Tanja Holopainen, Maria Wirzenius, Salla Keskitalo, Michael Jeltsch, Seppo Ylä-Herttuala, Stephen R. Wedge, Juliane M. Jürgensmeier, Kari Alitalo
Journal: Cancer Research
Cancer Res (2008) 68 (12): 4754–4762.
DOI: https://doi.org/10.1158/0008-5472.CAN-07-5809
Published: 16 June 2008
View article
PDF
Journal Articles

AZD1152: A highly potent and specific aurora kinase inhibitor.

Robert W. Wilkinson, Nicholas Keen, Rajesh Odedra, Simon P. Heaton, Stephen R. Wedge, Kevin M. Foote, Andrew A. Mortlock, Frederic H. Jung, Nicola M. Heron, Madeleine C. Brady, Mike Walker, Liz Khatri, Nigel C. Barrass, John J. Foster, Stephen Green
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1333–1334.
Published: 15 April 2006
View article
Journal Articles

Novel pyrazole- and thiazole-substituted quinazolines as potent aurora kinase inhibitors.

Andrew A. Mortlock, Kevin M. Foote, Nicola M. Heron, Frederic H. Jung, Nick Keen, Robert W. Wilkinson, Stephen R. Wedge, Madeleine C. Brady, Stephen Green, Liz Khatri, David McKillop
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1343–1344.
Published: 15 April 2006
View article
Journal Articles

Combining the highly potent, orally bioavailable, VEGF signaling inhibitor AZD2171 with radiotherapy in human tumor xenografts.

Kaye J. Williams, Brian A. Telfer, Ian J. Stratford, Stephen R. Wedge
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1343.
Published: 15 April 2006
View article
Journal Articles

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Stephen R. Wedge, Jane Kendrew, Laurent F. Hennequin, Paula J. Valentine, Simon T. Barry, Sandra R. Brave, Neil R. Smith, Neil H. James, Michael Dukes, Jon O. Curwen, Rosemary Chester, Janet A. Jackson, Sarah J. Boffey, Lyndsey L. Kilburn, Sharon Barnett, Graham H.P. Richmond, Peter F. Wadsworth, Mike Walker, Alison L. Bigley, Sian T. Taylor, Lee Cooper, Sarah Beck, Juliane M. Jürgensmeier, Donald J. Ogilvie
Journal: Cancer Research
Cancer Res (2005) 65 (10): 4389–4400.
DOI: https://doi.org/10.1158/0008-5472.CAN-04-4409
Published: 16 May 2005
View article
PDF
Journal Articles

AZD2171, a highly potent inhibitor of VEGF receptor signaling, has additional activity versus the c-Kit receptor tyrosine kinase

Juliane M. Jurgensmeier, Sandra R. Brave, Neil H. James, Stephen R. Wedge, Donald J. Ogilvie, Simon T. Barry
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1373.
Published: 01 May 2005
View article
Journal Articles

AZD2171, an orally active inhibitor of VEGFR tyrosine kinase activity, reduces polyp burden in a mouse model of intestinal cancer

Robert Goodlad, A. James Watkins, Richard Poulsom, Anderson J. Ryan, Stephen R. Wedge, Ian T. Pyrah, Nikki Mandir, Robert W. Wilkinson
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1374.
Published: 01 May 2005
View article
Journal Articles

The VEGF receptor tyrosine kinase inhibitor ZD6474 significantly reduces intestinal tumor burden in the Min mouse

Robert W. Wilkinson, Anderson J. Ryan, Stephen R. Wedge, Ian T. Pyrah, Nikki Mandir, Robert A. Goodlad
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 1075.
Published: 01 April 2004
View article
Journal Articles

AZD2171, a highly potent inhibitor of VEGF receptor tyrosine kinase activity, inhibits the growth of spontaneous mammary tumors in the MMTV-neu transgenic mouse

Teresa C. Klinowska, Janet A. Jackson, Paul M. Farrington, David S. Smith, Sharon Barnett, Lynsey Whittaker, Alison L. Bigley, Peter F. Wadsworth, Donald J. Ogilvie, Stephen R. Wedge
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 1048.
Published: 01 April 2004
View article
Journal Articles

Development and characterization in vivo of an inhibitor with Aurora kinase A and B specificity

Robert W. Wilkinson, Nick Keen, Stephen R. Wedge, Rajesh Odedra, Simon Heaton, Elaine Brown, Stephen Brightwell, Frederick Jung, Nicola Heron, Andrew Mortlock, Jack Allen, Sarah Kearney, John R. Foster, Stephen Green
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 193–194.
Published: 01 April 2004
View article
Journal Articles

Structure-activity relationship, physicochemical and pharmacokinetic properties of AZD2171: A highly potent inhibitor of VEGF receptor tyrosine kinases

Laurent F. Hennequin, Patrick Ple, Elaine S. Stokes, Stephen R. Wedge, Michael Dukes, Jane Kendrew, Jon O. Curwen, Mike Walker, Donald J. Ogilvie
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 1048.
Published: 01 April 2004
View article